Page Inspect

BioWorld: The Daily Biopharmaceutical and Medical Technology News Source





# BioWorld. Link to homepage.

- BioWorld
- BioWorld MedTech
- BioWorld Asia
- BioWorld Science
- Data Snapshots
- BioWorld
- BioWorld MedTech
- Infographics: Dynamic digital data analysis
- Index insights
- Special reports
- Infographics: Dynamic digital data analysis
- Trump administration impacts
- Under threat: mRNA vaccine research
- BioWorld at 35
- Biopharma M&A scorecard
- BioWorld 2024 review
- BioWorld MedTech 2024 review
- BioWorld Science 2024 review
- Women's health
- China's GLP-1 landscape
- PFA re-energizes afib market
- China CAR T
- Alzheimer's disease
- Coronavirus
- More reports can be found here

# BioWorld. Link to homepage.

- Sign In
- Sign Out
- My Account

Subscribe

BioWorld - Tuesday, October 28, 2025

BioWorldBioWorld MedTechBioWorld AsiaBioWorld Science

# BioWorld

- # In the year’s second largest M&A, Novartis buys Avidity for $12.5B

The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been...

More in BioWorld

# BioWorld MedTech

- # Penumbra takes TCT by STORM

Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in pulmonary embolism swept away in favor of...

More in BioWorld MedTech

# BioWorld Science

- # New modalities redefining druggability in genomically unstable cancers

At this year’s AACR-NCI-EORTC conference, several presentations brought to light new ways to tackle the treatment of genomically unstable cancers. Genomically unstable...

More in BioWorld Science

# BioWorld Asia

- # Aimedbio’s solid tumor ADC asset goes to Boehringer in $1B deal

Antibody-drug conjugate (ADC) specialist Aimedbio Inc. announced Oct. 16 the signing of a potential $991 million deal with Boehringer Ingelheim GmbH to license out its...

More in BioWorld Asia

### BioWorld Insider Podcast

Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment.

Listen now

- BioWorld
- Today's news
- Analysis and data insight
- Clinical
- Data Snapshots
- Deals and M&A
- Financings
- Newco news
- Opinion
- Regulatory
- Science

- BioWorld MedTech
- Today's news
- Clinical
- Data Snapshots
- Deals and M&A
- Financings
- Newco news
- Opinion
- Regulatory
- Science

- BioWorld Asia
- Today's news
- Analysis and data insight
- Australia
- China
- Clinical
- Deals and M&A
- Financings
- Newco news
- Regulatory
- Science

- BioWorld Science
- Today's news
- Biomarkers
- Cancer
- Conferences
- Endocrine/Metabolic
- Immune
- Infection
- Neurology/Psychiatric
- Patents

- More
- About
- Advertise with BioWorld
- Archives
- Article reprints and permissions
- Contact us
- Cookie policy
- Copyright notice
- Data methodology
- Infographics: Dynamic digital data analysis
- Index insights
- Podcasts
- Privacy policy
- Share your news with BioWorld
- Staff
- Terms of use
- Topic alerts

Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing
Cookie Settings